Trial Profile

Phase I Safety and Immunogenicity Trial of an Investigational RNActive Rabies Vaccine (CV7201) in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nadorameran (Primary) ; Nadorameran (Primary)
Indications Rabies
Focus Adverse reactions; First in man; Proof of concept
Sponsors CureVac

Most Recent Events

25 Oct 2018 Status changed from active, no longer recruiting to completed.
11 Jan 2017 Interim results published in a CureVac media release.
11 Jan 2017 Interim results presented at the 35th Annual J.P. Morgan Healthcare Conference, as per a CureVac media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com